IASLC

http://iaslc.org/

Last activity: 15.10.2026

Active

Categories: MedtechPublicScience

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other th ...

Facebook LinkedIn

Mentions

Mentions in press and media 25

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Sep 15, 2026	Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026	HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) ...
Jul 27, 2025	Karen Kelly, MD, Named 2025 Bonnie J. Addario Lectureship Award Honoree	GO2 for Lung Cancer and the Addario Lung Cancer Medical Institute recognize Dr. Kelly's leadership and impact on the lung cancer community Dr. Kelly has elevated global conversation and advanced real progress in science and care. But what m...
Sep 11, 2024	AI Shows Promise in Early Lung Cancer Detection via Chest X-rays	What You Should Know: – A new study presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer offers exciting possibilities for early lung cancer detection. – Researchers at Phrapok...
Sep 10, 2024	Datopotamab Deruxtecan Does Not Meet Its Secondary Primary Endpoint in TROPION-Lung01	Dr. Jacob Sands, Dana-Farber Cancer Institute in Boston, Mass. The therapy datopotamab deruxtecan did not meet its secondary dual primary end point of overall survival for patients with advanced non-small cell lung cancer but it did show a ...
Sep 10, 2024	LUMINOSITY Trial Demonstrates Telisotuzumab Vedotin Shows Durable Response in Asian Patients with c-Met Protein-Overexpressing EGFR WT Nonsquamous NSCLC	Dr. Hidehito Horinouchi, of the National Cancer Center Hospital in Japan SAN DIEGO, Calif., Sept. 10, 2024 /PRNewswire-PRWeb/ -- The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptab...
Sep 10, 2024	Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer	Dr. Geoffrey Liu, from Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Canada. The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable ...
Sep 10, 2024	PM2.5 Exposure May Affect Lung Cancer in Women Who Have Never Smoked	Dr. Yixian Chen, a researcher at British Columbia Cancer Research Institute, Vancouver, Canada. Recent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may significantly impact lung cancer in wom...
Sep 9, 2024	Results from the FURTHER Trial Demonstrate Firmonertinib is a Promising Potential Therapy for Patients with NSCLC with EGFR PACC Mutations	Dr. David Planchard, an investigator from Institut Gustave Roussy The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-lin...
Sep 9, 2024	Breakthrough Therapy BAY 2927088 Demonstrates 'Rapid, Substantial and Durable Responses' in Patients with HER2-Mutant NSCLC	Xiuning Le, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, Houston Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCL...
Sep 9, 2024	Osimertinib With Savolitinib Demonstrates Stronger Efficacy Than Osimertinib Alone in Patients Who Do Not Respond Well to EGFR-TKIs Therapy	Jin-Ji Yang, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital in Southern Medical University, China. The combination of osimertinib and savolitinib showed clinically meaningful improvement in objective response rate c...
Sep 9, 2024	Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Improves PFS Compared to Placebo	Dr. Xiangjiao Meng of the Shandong Cancer Hospital and Institute, Shandong First Medical University, China The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared ...
Sep 8, 2024	PanCan Nodule Management Protocol More Effective Than LungRADSv1.1 Method	Dr. Annette McWilliams, Fiona Stanley Hospital, Australia New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening participants compared to the LungRADSv...
Sep 8, 2024	Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study	Dr. Caicun Zhou, Shanghai Pulmonary Hospital in Shanghai, China Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pemb...
Sep 8, 2024	Perioperative Nivolumab May Provide Meaningful Improvement in Event-Free Survival Compared to only Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC	Dr. Patrick Forde of The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney Kimmel Comprehensive Cancer New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with res...
Sep 8, 2024	NeoCOAST-2 Data Shows Combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data Builds on AEGEAN Study Research	Dr. Tina Cascone, from The University of Texas MD Anderson Cancer Center in Houston. Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response ...
Sep 7, 2024	IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing	Matthew Smeltzer, PhD, of the University of Memphis, Memphis, Tenn. Despite significant improvements in the perception of biomarker testing compared to a 2018 survey, substantial barriers to implementation persist globally, according to res...
Sep 7, 2024	Antibody-Drug Conjugate I-DXd Shows Clinically Meaningful Response in Patients with Extensive-Stage Small Cell Lung Cancer	Dr. C.M. Rudin of Memorial Sloan Kettering Cancer Center in New York City The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (E...
Jul 7, 2022	Pharmacists 'ready to get to work' after new FDA authorization allows them to prescribe Pfizer's Covid-19 antiviral	Amgen is showing off the last, breakthrough round of data it has from the pivotal study for its KRAS G12C drug sotorasib in non-small cell lung cancer — the data they’ll be going to market with, if regulators come through with an accelerate...
Sep 12, 2021	Neoadjuvant Atezolizumab in Combination with Cisplatin/Pemetrexed and as Maintenance for Resectable Pleural Mesothelioma Meets Safety Criteria	“Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria,” said Dr. Tsao. Denver, Colorado (PRWEB) September 12, 2021 Neoadjuvant Atezolizumab in Combination wit...
Sep 12, 2021	Almost two thirds of thoracic oncologists used telehealth for the first-time during pandemic: IASLC survey	“Much will need to be done to counteract the negative impacts on care, clinical trials, and research during the COVID-19 pandemic,” said Anne-Marie Baird, Ph.D., Trinity College Dublin, Dublin, Ireland and chair of the IALSC Communications ...
Sep 11, 2021	Phase III POSEIDON Trial Shows Positive Results for Patients Taking Chemotherapy Plus Durvalumab and Tremelimumab	“The POSEIDON trial showed that patients who received durvalumab and tremelimumab and chemotherapy experienced statistically significant and clinically meaningful improvements in both progression-free survival and overall survival compared ...
Sep 9, 2021	COVID-19 Pandemic Significantly Reduced Lung Cancer Clinical Trial Enrollment	“Clinical trial enrollment declined by 43 percent from 2019 to 2020, with the most dramatic decrease in April to August of 2020,” reported Matthew Smeltzer, PhD, University of Memphis, Memphis, Tenn. DENVER (PRWEB) September 09, 2021 IASLC ...
Jan 24, 2018	Clearing the Air About Smoking in Japan	Japan tends to top the lists of countries ranked by average life expectancy. This is usually attributed to the Japanese diet, which favors fish over red meat; the popularity of walking and cycling in the country; and a family model that ens...
	Improving implementation of biomarker testing advances precision medicine in lung cancer	Advances in precision medicine continue to enhance the lung cancer treatment landscape, which is great news for patients and doctors. New therapies that target specific proteins linked to genetic mutations have the potential to improve outc...

Reviews 0

FAQ about IASLC

What has the press written about IASLC?

Parsers VC has collected 25 articles mentioning IASLC, among them “Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026” (Sep 15, 2026) and “Karen Kelly, MD, Named 2025 Bonnie J. Addario Lectureship Award Honoree” (Jul 27, 2025).

Is IASLC still active?

Yes, IASLC is active; its latest activity on Parsers VC dates from Oct 15, 2026.